Point72 Asset Management
KPTI icon

Point72 Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Point72 Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,667
Closed -$1.7M – 1094
2018
Q3 		$1.7M Buy
+6,667
New +$1.84M 0.01% 780

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Point72 Asset Management's KPTI Position: Q4 2023 in Review

Point72 Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 18 shares — an estimated $364 sold.

Point72 Asset Management first reported a position in KPTI in Q2 2014 and held it in 12 quarters. The position peaked at $32.2M in Q4 2017. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

  • Point72 Asset Management reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 18 Karyopharm Therapeutics shares in Q4 2023, an estimated $364.
  • Point72 Asset Management first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 12 quarters.
  • Point72 Asset Management's Karyopharm Therapeutics position peaked at $32.2M in Q4 2017.
  • 117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.